Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop

Brazil-Itajai

The small city of Itajai, Brazil has offered Ivermectin to its citizens and the results were wonderful. The hospitalizations and deaths that the city experienced were cut in half.

According to ZeroHedge:

Between July and December of 2020, roughly 220,000 people were offered a dose of 0.2mg/kg/day (roughly 18mg for a 200lb person) as an optional treatment for 2 days, once every two weeks.

133,051 people took them up on it, while 87,466 did not.

After analyzing the data, a team of researchers spanning several Brazilian institutes, the University of Toronto, and Columbia’s EAFIT concluded in a December pre-print study that hospitalization and mortality rates were cut in half over the seven month period among the Ivermectin group.

Why hasn’t this been all over the MSM? Why isn’t anybody else reporting on these fantastic numbers?

Since Ivermectin has been talked about “scientists” and others on the left have screamed to the skies that this medication simply would never work. It was nothing more than a horse paste. You are a conspiracy theorist if you believe it helps at all.

As time went on we saw multiple people come forward touting Ivermectin helped them combat Covid. People from President Donald Trump, Joe Rogan, 200 members of Congress, to doctors who lost their jobs for trying something different to save their patients.

Fact-checkers limited our posts and called us liars for saying “well if this works, why not try it?”

A study that you can find here discussed the city of Itajai, Brazil and their results.

Abstract

Background: Ivermectin has demonstrated different mechanisms of actions that could potentially protect from both COVID-19 infection and COVID-19-related comorbidities. Based on the existing literature and safety profile of ivermectin, a citywide program of prophylactic use of ivermectin for COVID-19 was implemented in Itajai, a Southern city in Brazil in the state of Santa Catarina. The objective of this analysis is to evaluate the effects of the use of ivermectin for prevention of COVID-19 infection, risk of dying and mortality, compared to non-users.

Materials and methods: This is a retrospective analysis of registry data from the medical based citywide COVID-19 prevention with ivermectin program, between July 2020 to December of 2020. The whole population of Itajaí was invited for a medical visit to 

compile demographic and medical parameters. In the absence of contraindications, ivermectin was offered as an optional treatment for 2 days every 15 days at a dose of 0.2mg/kg/day. Patients’ preferences and medical autonomy were preserved. Ivermectin users were compared with the comorbidity-matched population of non-users for 

COVID19 by age, sex, COVID-19 infection rate, and COVID-19 mortality rate. Results in terms of mortality were adjusted for all relevant variables and Propensity Score Matching (PSM) was calculated.

Results: A total of 220,517 subjects were included in the analysis; 133,051 (60.3%) ivermectin users and 87,466 (39.7%) non-users. COVID-19 infection occurred in 4,311 (3.2%) treated subjects, and 3,034 (3.5%) non-treated subjects. 

This evidence showed a 7% reduction in COVID-19 infection rate with use of ivermectin: COVID-19 infection rate ratio (Risk ratio (RR) of 0.93; 95% confidence interval (CI), 0.89 – 0.98; p = 0.003). A total of 62 deaths (1.4% mortality rate) occurred among users and 79 deaths (2.6% mortality rate) among non-users, showing a 48% reduction in mortality rate (RR, 0,52; 95%CI, 0.37 – 0.72; p = 0.0001). 

Risk of dying from COVID-19 among ivermectin users was 45% lower than non-users (RR, 0.55; 95%CI, 0.40 – 0.77; p = 0.0004).

Conclusion: Prophylactic use of ivermectin showed significantly reduced COVID-19 infection rate, mortality rate and the chance of dying from COVID-19 on a calculated population-level analysis, which controlled for all relevant confounding variables.

  • Itajai
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 1
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 2
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 3
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 4
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 5
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 6
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 7
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 8
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 9
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 10
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 11
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 12
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 13
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 14
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 15
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 16
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 17
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 18
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 19
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 20
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 21
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 22
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 23
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 24
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 25
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 26
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 27
  • Itajai, Brazil Offered Ivermectin as Prophylaxis, Hospitalizations and Mortality Rates Drop 28

There have also been a few studies funded by the Indian government that was conducted mainly through their government public medical university. (AIIMS0

  • Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study (source)

Conclusion: Two-dose ivermectin prophylaxis at a dose of 300 ?g/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month.

  • Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial (source)

Conclusion: There was no difference in the primary outcome i.e. negative RT-PCR status on day 6 of admission with the use of ivermectin. However, a significantly higher proportion of patients were discharged alive from the hospital when they received ivermectin.

  • Clinical Research Report Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial (source, double-blind randomized, peer-reviewed)

Discussion: In the present study, patients with mild or moderate COVID-19 infection treated with ivermectin in combination with doxycycline generally recovered 2 days earlier than those treated with placebo. The proportion of patients responding within 7 days of treatment was significantly higher in the treatment group than in the placebo group. The proportions of patients who remained symptomatic after 12 days of illness and who experienced disease progression were significantly lower in the treatment group than in the placebo group.

India isn’t the only country that is exploring the Ivermectin option to save its citizens.

Peru:

  • Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments (source, peer-reviewed, University of Toronto, Universidad EAFIT)

For the 24 states with early IVM treatment (and Lima), excess deaths dropped 59% (25%) at +30 days and 75% (25%) at +45 days after day of peak deaths. Case fatalities likewise dropped sharply in all states but Lima

Spain:

  • The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial (source, University of Barcelona, peer-reviewed)

Findings: Patients in the ivermectin group recovered earlier from hyposmia/anosmia (76 vs 158 patient-days; p < 0.001).

Bengladesh:

  • A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients (source – peer reviewed, though not govt funded)

Conclusion: According  to  our  study,  the  Ivermectin-Doxycycline combination therapy has better symptomatic relief, shortened recovery duration, fewer adverse effects, and superior patient compliance compared to the Hydroxychloroquine-Azithromycin combination. Based on this  study’s  outcomes,  the  Ivermectin-Doxycycline  combination  is  a  superior  choice  for  treating  patients  with  mild to moderate COVID-19 disease.

  • A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness (source, peer-reviewed double blind randomized, though small sample size)

Discussion: A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo (p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host. In the 5-day ivermectin group, there was a significant drop in CRP and LDH by day 7, which are indicators of disease severity.

While other countries are veering off the course that WHO and Fraudci have put in place, they are seeing improvements with their hospitalizations and deaths. Meanwhile, if you even think about questioning your government here or their science you’re screamed at. A popular question that I’m always asked when I express my opinions or the fact that I prefer medical freedom is “Who do you think you are? Why do you think you have the right to question the government and doctors?”

I think I’m someone who doesn’t agree with any type of tyranny and believes that everyone should have the freedom to make their own decisions when it comes to forceful vaccination.

0 0 votes
Article Rating

Powered By WordPress | Royal News Magazine Pro

0
Would love your thoughts, please comment.x
()
x